Nanoform and Pharmanovia to breathe new life into iconic medicines
Thursday, July 14, 2022
Nanoform Finland Plc., an innovative company specializing in nanoparticle medicine technology, has announced a strategic partnership with Pharmanovia, a rapidly expanding specialty pharmaceutical company with a portfolio of over 20 branded drugs available in 140 markets.
The primary objective of this collaboration is to enhance the value of branded prescription medicines. Pharmanovia intends to leverage Nanoform's proprietary nanoparticle technologies and formulation expertise to improve the performance of established pharmaceutical brands.
The partnership commences with a focus on an iconic branded medicine, where both parties recognize the potential for enhancing bioavailability to benefit patients. The agreement follows Nanoform's business model for non-GMP and cGMP work and progresses in stages.
"This partnership exemplifies how the power of small can generate added value for iconic medicines, making them even more effective. Pharmanovia's business model facilitates the continuity of brand loyalty across generations," commented Christian Jones, Chief Commercial Officer of Nanoform.
